Skip to main content

Table 3 Follow up of patients injected with M-FP

From: Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]

Patient number Age (years) Date of surgery Type of treatment Tumour size (cm) Total nodes Metastatic nodes Grade Date of first injection Side effects Recurrence Last follow up Follow up (months)
1 58 02/12/97 Partial mast + RT + tam 1.0 17 1 II 21/01/98 Mild skin redness - 13/06/05 90
2 72 14/01/98 Total mast + tam 2.0 12 1 I 03/02/98 Mild skin redness - 13/06/05 89
3 52 24/03/98 Partial mast + RT + tam 1.3 20 2 II 16/11/98 - - 13/06/05 87
4 53 22/05/98 Partial mast + RT + tam 1.5 23 2 III 30/11/98 - - 15/06/05 85
5 53 03/09/98 Total mast + tam 3.0 21 4 a 23/09/98 - - 15/06/05 81
6 58 10/11/98 Total mast + tam 1.5 22 3 II 30/11/98 Mild skin redness - 15/06/05 79
7 78 08/12/98 Bilateral total mast +tam Right 1.2 Left 1.2 18 16 0 4 I I 28/12/98 - - 17/06/05 78
8 62 27/01/99 Partial mast + RT + tam 1.0 8 1 II 16/02/99 Mild skin redness - 17/06/05 77
9 61 01/04/99 Partial mast + RT + tam 2.0 18 1 I 26/04/99 - - 17/06/05 74
10 58 21/04/99 Partial mast + RT + tam 2.0 17 3 II 07/05/99 - - 20/06/05 74
11 53 13/07/99 Partial mast + RT + tam 2.3 29 1 a 19/08/99 Mild skin redness - 20/06/05 71
12 59 16/09/99 Total mast + tam 1.4 19 1 I 26/06/00 - - 20/06/05 69
13 59 10/11/99 Total mast + tam 0.7 10 1 a 22/11/99 -   22/06/05 67
14 63 09/02/00 Partial mast + RT + tam 1.2 13 1 II 01/03/00 - - 22/06/05 64
15 55 10/02/00 Partial mast + RT + tam 2.5 23 3 II 25/02/00 - - 24/06/05 64
16 65 29/06/00 Partial mast + RT + tam 0.8 17 1 II 17/07/00 Mild skin redness - 24/06/05 60
  1. aThe histologic type was invasive lobular adenocarcinoma with no grading. mast, mastectomy; M-FP, oxidized mannan conjugated to MUC1 fusion protein; RT, radiotherapy; tam, tamoxifen.